1.17
1.17 (0%)
As of Oct 23, 2024
Ocuphire Pharma, Inc. [OCUP]
Source:
Company Overview
Opus Genetics, Inc is a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (“IRDs”) and other types of therapies for additional ophthalmic disorders.
| Country | United States |
| Headquarters | farmington hills, michigan |
| Phone Number | (248) 957-9024 |
| Industry | manufacturing |
| CEO | George Magrath |
| Website | opusgtx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $11 |
| Operating Profit | $-62.1 |
| Net Income | $-57.5 |
| Net Cash | $-20.2 |
Profit Ratios
| Gross Margin | $11 |
| Operating Margin | -564.7 |
| Profit as % of Revenues | -19.1% |
| Profit as % of Assets | -126.7% |
| Profit as % of Stockholder Equity | -855.6% |
Management Effectiveness
| Return on Equity | -855.6% |
| Return on Assets | -156.1% |
| Turnover Ratio | 24.2% |
| EBITA | $-62.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $36.9 |
| Total Liabilities | $11.3 |
| Operating Cash Flow | $-25.6 |
| Investing Cash Flow | $1.2 |
| Financing Cash Flow | $4.2 |
